Published in J Clin Oncol on April 09, 2012
Adverse Health Events Following Intermittent and Continuous Androgen Deprivation in Patients With Metastatic Prostate Cancer. JAMA Oncol (2016) 1.56
Management of cancer treatment-induced bone loss. Nat Rev Rheumatol (2013) 0.99
Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl (2012) 0.95
Osteoporosis and cancer. Curr Osteoporos Rep (2013) 0.80
Prostate cancer: Bone density testing--essential or extraneous? Nat Rev Urol (2012) 0.75
Relationships between times to testosterone and prostate-specific antigen rises during the first off-treatment interval of intermittent androgen deprivation are prognostic for castration resistance in men with nonmetastatic prostate cancer. Clin Genitourin Cancer (2014) 0.75
Meta-analysis of how well measures of bone mineral density predict occurrence of osteoporotic fractures. BMJ (1996) 11.60
Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med (2005) 8.32
Denosumab in men receiving androgen-deprivation therapy for prostate cancer. N Engl J Med (2009) 6.67
EAU guidelines on prostate cancer. Eur Urol (2007) 6.30
Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy. Lancet Oncol (2006) 4.64
Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol (2007) 3.91
Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med (2001) 3.78
Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer. J Clin Oncol (2007) 3.65
Increasing use of gonadotropin-releasing hormone agonists for the treatment of localized prostate carcinoma. Cancer (2005) 3.56
Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol (2005) 2.87
Effect of once-weekly oral alendronate on bone loss in men receiving androgen deprivation therapy for prostate cancer: a randomized trial. Ann Intern Med (2007) 2.54
Standardization of bone mineral density at femoral neck, trochanter and Ward's triangle. Osteoporos Int (2001) 2.25
Bone loss after initiation of androgen deprivation therapy in patients with prostate cancer. J Clin Endocrinol Metab (2005) 2.23
Risk of clinical fractures after gonadotropin-releasing hormone agonist therapy for prostate cancer. J Urol (2006) 1.89
Universal standardization of bone density measurements: a method with optimal properties for calibration among several instruments. J Bone Miner Res (1997) 1.73
Intermittent versus continuous total androgen blockade in the treatment of patients with advanced hormone-naive prostate cancer: results of a prospective randomized multicenter trial. Clin Prostate Cancer (2002) 1.55
Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer. Urology (2007) 1.29
The effect of zoledronic acid on bone mineral density in patients undergoing androgen deprivation therapy. Clin Genitourin Cancer (2007) 1.27
Long-term effects of intermittent androgen suppression on testosterone recovery and bone mineral density: results of a 33-month observational study. BJU Int (2009) 1.22
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol (2010) 1.12
Quality of life, morbidity, and mortality results of a prospective phase II study of intermittent androgen suppression for men with evidence of prostate-specific antigen relapse after radiation therapy for locally advanced prostate cancer. Clin Genitourin Cancer (2008) 1.12
Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer. Eur J Cancer (2006) 1.10
Adjuvant hormonal treatment with radiotherapy for locally advanced prostate cancer. Eur Urol (1999) 1.06
Complications of androgen deprivation therapy in prostate cancer. Curr Opin Urol (2009) 1.06
The effect of androgen deprivation therapy on body composition in men with prostate cancer: systematic review and meta-analysis. J Cancer Surviv (2010) 0.95
Androgen deprivation therapy and risk for diabetes and cardiovascular disease in prostate cancer survivors. Curr Urol Rep (2008) 0.94
Alendronate decreases the fracture risk in patients with prostate cancer on androgen-deprivation therapy and with severe osteopenia or osteoporosis. BJU Int (2009) 0.92
Intermittent androgen suppression for locally advanced and metastatic prostate cancer: preliminary report of a prospective multicenter study. Urology (2004) 0.90
Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med (2010) 29.75
Abiraterone in metastatic prostate cancer without previous chemotherapy. N Engl J Med (2012) 15.69
Development of a second-generation antiandrogen for treatment of advanced prostate cancer. Science (2009) 13.87
Enzalutamide in metastatic prostate cancer before chemotherapy. N Engl J Med (2014) 11.05
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study. Lancet (2010) 10.79
Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res (2008) 10.66
Intermittent androgen suppression for rising PSA level after radiotherapy. N Engl J Med (2012) 8.64
Lead time and overdiagnosis in prostate-specific antigen screening: importance of methods and context. J Natl Cancer Inst (2009) 6.96
Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol (2007) 6.73
Intermittent versus continuous androgen deprivation in prostate cancer. N Engl J Med (2013) 6.17
Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol (2006) 5.72
Natural history of rising serum prostate-specific antigen in men with castrate nonmetastatic prostate cancer. J Clin Oncol (2005) 3.22
Phenotypic heterogeneity of end-stage prostate carcinoma metastatic to bone. Hum Pathol (2003) 3.17
Double-blinded randomized study of high-dose calcitriol plus docetaxel compared with placebo plus docetaxel in androgen-independent prostate cancer: a report from the ASCENT Investigators. J Clin Oncol (2007) 3.05
Quantifying the role of PSA screening in the US prostate cancer mortality decline. Cancer Causes Control (2007) 2.69
Age-associated decrease in TLR function in primary human dendritic cells predicts influenza vaccine response. J Immunol (2010) 2.63
The prostate cancer conundrum revisited: treatment changes and prostate cancer mortality declines. Cancer (2012) 2.61
Nevirapine (NVP) resistance in women with HIV-1 subtype C, compared with subtypes A and D, after the administration of single-dose NVP. J Infect Dis (2005) 2.54
Long-term projections of the harm-benefit trade-off in prostate cancer screening are more favorable than previous short-term estimates. J Clin Epidemiol (2011) 2.46
Prostate cancer, version 2.2014. J Natl Compr Canc Netw (2014) 2.40
A human monoclonal autoantibody to the thyrotropin receptor with thyroid-stimulating blocking activity. Thyroid (2008) 2.35
Glucose dysregulation and hepatic steatosis in obese adolescents: is there a link? Hepatology (2009) 2.33
Nevirapine and zidovudine at birth to reduce perinatal transmission of HIV in an African setting: a randomized controlled trial. JAMA (2004) 2.31
Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial. Lancet Oncol (2013) 2.29
Circulating tumor cell counts are prognostic of overall survival in SWOG S0421: a phase III trial of docetaxel with or without atrasentan for metastatic castration-resistant prostate cancer. J Clin Oncol (2014) 2.19
Zoledronic acid exhibits inhibitory effects on osteoblastic and osteolytic metastases of prostate cancer. Clin Cancer Res (2003) 2.14
Late postnatal transmission of HIV-1 and associated factors. J Infect Dis (2007) 2.11
PROVENGE (Sipuleucel-T) in prostate cancer: the first FDA-approved therapeutic cancer vaccine. Clin Cancer Res (2011) 2.10
Estimating lead time and overdiagnosis associated with PSA screening from prostate cancer incidence trends. Biometrics (2007) 2.09
Impact of PSA screening on the incidence of advanced stage prostate cancer in the United States: a surveillance modeling approach. Med Decis Making (2008) 2.06
Phase III, randomized, placebo-controlled study of docetaxel in combination with zibotentan in patients with metastatic castration-resistant prostate cancer. J Clin Oncol (2013) 1.95
Quantitative analysis of HIV-1 variants with the K103N resistance mutation after single-dose nevirapine in women with HIV-1 subtypes A, C, and D. J Acquir Immune Defic Syndr (2006) 1.94
Histopathological assessment of prostate cancer bone osteoblastic metastases. J Urol (2008) 1.91
Limitations of basing screening policies on screening trials: The US Preventive Services Task Force and Prostate Cancer Screening. Med Care (2013) 1.88
Prostate cancer, Version 3.2012: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2012) 1.84
Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening. Ann Intern Med (2013) 1.84
Osteoporosis in men with prostate carcinoma receiving androgen-deprivation therapy: recommendations for diagnosis and therapies. Cancer (2004) 1.69
Prostate-specific antigen progression predicts overall survival in patients with metastatic prostate cancer: data from Southwest Oncology Group Trials 9346 (Intergroup Study 0162) and 9916. J Clin Oncol (2009) 1.67
Risk factors for hospital admission among older persons with newly diagnosed heart failure: findings from the Cardiovascular Health Study. J Am Coll Cardiol (2013) 1.67
Improved HIV and substance abuse treatment outcomes for released HIV-infected prisoners: the impact of buprenorphine treatment. J Urban Health (2010) 1.66
Improved overall survival trends of men with newly diagnosed M1 prostate cancer: a SWOG phase III trial experience (S8494, S8894 and S9346). J Urol (2012) 1.65
The impact of breastfeeding on the health of HIV-positive mothers and their children in sub-Saharan Africa. Bull World Health Organ (2006) 1.59
The role of sipuleucel-T in therapy for castration-resistant prostate cancer: a critical analysis of the literature. Eur Urol (2011) 1.59
Resistance after single-dose nevirapine prophylaxis emerges in a high proportion of Malawian newborns. AIDS (2005) 1.58
Pharmacological inhibition of myostatin and changes in lean body mass and lower extremity muscle size in patients receiving androgen deprivation therapy for prostate cancer. J Clin Endocrinol Metab (2014) 1.53
A rice gene activation/knockout mutant resource for high throughput functional genomics. Plant Mol Biol (2006) 1.50
Diversity and phylogenetic analysis of bacteria in the mucosa of chicken ceca and comparison with bacteria in the cecal lumen. FEMS Microbiol Lett (2002) 1.49
Incidence of second malignancies after external beam radiotherapy for clinical stage I testicular seminoma. BJU Int (2011) 1.48
Comparative analyses of chromosome alterations in soft-tissue metastases within and across patients with castration-resistant prostate cancer. Cancer Res (2009) 1.42
Effects of cessation of breastfeeding in HIV-1-exposed, uninfected children in Malawi. Clin Infect Dis (2011) 1.42
Differential expression of angiogenesis associated genes in prostate cancer bone, liver and lymph node metastases. Clin Exp Metastasis (2007) 1.41
Should modest elevations in prostate-specific antigen, International Prostate Symptom Score, or their rates of increase over time be used as surrogate measures of incident benign prostatic hyperplasia? Am J Epidemiol (2013) 1.41
American Society of Clinical Oncology endorsement of the Cancer Care Ontario Practice Guideline on nonhormonal therapy for men with metastatic hormone-refractory (castration-resistant) prostate cancer. J Clin Oncol (2007) 1.41
Age-associated elevation in TLR5 leads to increased inflammatory responses in the elderly. Aging Cell (2011) 1.39
Sipuleucel-T. Nat Rev Drug Discov (2010) 1.37
Primary defects in beta-cell function further exacerbated by worsening of insulin resistance mark the development of impaired glucose tolerance in obese adolescents. Diabetes Care (2008) 1.35
Personalizing age of cancer screening cessation based on comorbid conditions: model estimates of harms and benefits. Ann Intern Med (2014) 1.32
Prostate cancer, version 1.2014. J Natl Compr Canc Netw (2013) 1.32
Development of a procedure for discriminating among Escherichia coli isolates from animal and human sources. Appl Environ Microbiol (2002) 1.29
Autoimmune oophoritis as a mechanism of follicular dysfunction in women with 46,XX spontaneous premature ovarian failure. Fertil Steril (2005) 1.26
Coordinated responses to oxygen and sugar deficiency allow rice seedlings to tolerate flooding. Sci Signal (2009) 1.25
Sensitivity of the ViroSeq HIV-1 genotyping system for detection of the K103N resistance mutation in HIV-1 subtypes A, C, and D. J Mol Diagn (2006) 1.25
Prostate cancer mortality following active surveillance versus immediate radical prostatectomy. Clin Cancer Res (2012) 1.25
Erectile function outcome reporting after clinically localized prostate cancer treatment. J Urol (2007) 1.25
Molecular analysis of bacterial populations in the ileum of broiler chickens and comparison with bacteria in the cecum. FEMS Microbiol Ecol (2002) 1.23
C11-acetate and F-18 FDG PET for men with prostate cancer bone metastases: relative findings and response to therapy. Clin Nucl Med (2011) 1.23
Genetic modifiers affecting severity of epilepsy caused by mutation of sodium channel Scn2a. Mamm Genome (2005) 1.22
Elevation of cytokine levels in cachectic patients with prostate carcinoma. Cancer (2003) 1.18
Associations of very high intakes of eicosapentaenoic and docosahexaenoic acids with biomarkers of chronic disease risk among Yup'ik Eskimos. Am J Clin Nutr (2010) 1.17
Refractory colitis following anti-CTLA4 antibody therapy: analysis of mucosal FOXP3+ T cells. Dig Dis Sci (2009) 1.15
CCL2 is induced by chemotherapy and protects prostate cancer cells from docetaxel-induced cytotoxicity. Prostate (2010) 1.14
Targeted androgen pathway suppression in localized prostate cancer: a pilot study. J Clin Oncol (2013) 1.14
Multimarker circulating DNA assay for assessing blood of prostate cancer patients. Clin Chem (2009) 1.14
Duration of first off-treatment interval is prognostic for time to castration resistance and death in men with biochemical relapse of prostate cancer treated on a prospective trial of intermittent androgen deprivation. J Clin Oncol (2010) 1.12
Knowledge of evidence-based urinary catheter care practice recommendations among healthcare workers in nursing homes. J Am Geriatr Soc (2010) 1.12
Development of near-isogenic lines and identification of markers linked to auxinic herbicide resistance in wild mustard (Sinapis arvensis L.). Pest Manag Sci (2012) 1.12
Depression and symptomatic response among HIV-infected drug users enrolled in a randomized controlled trial of directly administered antiretroviral therapy. AIDS Care (2009) 1.11
AIRE gene mutations and autoantibodies to interferon omega in patients with chronic hypoparathyroidism without APECED. Clin Endocrinol (Oxf) (2010) 1.11
Cell phone based balance trainer. J Neuroeng Rehabil (2012) 1.11
Development of nevirapine resistance in infants is reduced by use of infant-only single-dose nevirapine plus zidovudine postexposure prophylaxis for the prevention of mother-to-child transmission of HIV-1. J Infect Dis (2006) 1.11
Perturbation of NK cell peripheral homeostasis accelerates prostate carcinoma metastasis. J Clin Invest (2013) 1.10
The stability of silver nanoparticles in a model of pulmonary surfactant. Environ Sci Technol (2013) 1.09
Interleukin-23: as a drug target for autoimmune inflammatory diseases. Immunology (2012) 1.07
Effects of androgen deprivation therapy and bisphosphonate treatment on bone in patients with metastatic castration-resistant prostate cancer: results from the University of Washington Rapid Autopsy Series. J Bone Miner Res (2013) 1.07
Phase I study of weekly mitoxantrone and docetaxel before prostatectomy in patients with high-risk localized prostate cancer. Clin Cancer Res (2004) 1.06
Variants of the natural resistance-associated macrophage protein 1 gene (NRAMP1) are associated with severe forms of pulmonary tuberculosis. Clin Infect Dis (2005) 1.06
Late expression of p53 from a replicating adenovirus improves tumor cell killing and is more tumor cell specific than expression of the adenoviral death protein. Hum Gene Ther (2002) 1.05
Increasing use of radical prostatectomy for nonlethal prostate cancer in Sweden. Clin Cancer Res (2012) 1.03
Cabozantinib inhibits growth of androgen-sensitive and castration-resistant prostate cancer and affects bone remodeling. PLoS One (2013) 1.03
Feasibility of cranberry capsule administration and clean-catch urine collection in long-term care residents. J Am Geriatr Soc (2010) 1.03
Estimated risk for developing autoimmune Addison's disease in patients with adrenal cortex autoantibodies. J Clin Endocrinol Metab (2006) 1.02
Phase II study of KOS-862 in patients with metastatic androgen independent prostate cancer previously treated with docetaxel. Invest New Drugs (2007) 1.01
Intermittent intravaginal antibiotic treatment of bacterial vaginosis in HIV-uninfected and -infected women: a randomized clinical trial. PLoS Clin Trials (2007) 1.01
Metastases of prostate cancer express estrogen receptor-beta. Urology (2004) 1.01
Molecular alterations in prostate carcinomas that associate with in vivo exposure to chemotherapy: identification of a cytoprotective mechanism involving growth differentiation factor 15. Clin Cancer Res (2007) 1.00
Recurrent urinary tract infection and urinary Escherichia coli in women ingesting cranberry juice daily: a randomized controlled trial. Mayo Clin Proc (2012) 1.00